Cancer-Selective Cell-Penetrating Peptide Delivers miRNA to Kill Tumor Cells Safely
A peptide derived from hexokinase II selectively enters and kills cancer cells while delivering tumor-suppressor miR-126, with no toxicity to normal cells.
Quick Facts
What This Study Found
PAS-pHK peptide delivers miR-126 selectively to cancer cells, targeting mitochondria to induce apoptosis synergistically while showing no toxicity to non-cancerous cells.
Key Numbers
PAS-pHK from N-terminal 15 amino acids of HKII; miR-126 synergistically enhanced anti-cancer effects; no toxicity to MCF-10A or HEK-93
How They Did This
In-vitro study designing a hexokinase II-derived CPP conjugated to miR-126 mimic, measuring cellular uptake, mitochondrial effects, ATP depletion, apoptosis, and selectivity in cancer vs. normal cell lines.
Why This Research Matters
Selective cancer cell killing without harming normal cells is the holy grail of cancer therapy. This peptide-miRNA approach achieves selectivity by exploiting cancer-specific hexokinase II overexpression.
The Bigger Picture
This combines two cancer-fighting strategies — metabolic disruption via mitochondrial targeting and gene silencing via miRNA delivery — into a single cancer-selective peptide conjugate.
What This Study Doesn't Tell Us
In-vitro only with limited cell line testing; no in-vivo tumor model; peptide stability in blood and biodistribution unknown; manufacturing of peptide-miRNA conjugates at scale not addressed.
Questions This Raises
- ?Does PAS-pHK-miR-126 show cancer selectivity and efficacy in animal tumor models?
- ?How does the conjugate perform in heterogeneous tumors with varying HKII expression?
- ?Can this platform deliver other therapeutic miRNAs beyond miR-126?
Trust & Context
- Key Stat:
- Cancer-selective, normal cells spared PAS-pHK-miR-126 killed breast cancer MCF-7 cells but showed no toxicity to non-cancerous MCF-10A and HEK-293 cells
- Evidence Grade:
- Compelling in-vitro proof of concept with cancer selectivity demonstrated across multiple cell lines, but requires in-vivo validation.
- Study Age:
- Published in 2020; peptide-miRNA conjugates for selective cancer therapy remain an active research area.
- Original Title:
- Hexokinase II-Derived Cell-Penetrating Peptide Mediates Delivery of MicroRNA Mimic for Cancer-Selective Cytotoxicity.
- Published In:
- Biochemistry, 59(24), 2259-2273 (2020)
- Database ID:
- RPEP-05048
Evidence Hierarchy
Frequently Asked Questions
Can peptides kill cancer cells selectively?
Yes — PAS-pHK targets hexokinase II on cancer cell mitochondria, killing cancer cells through metabolic disruption while sparing normal cells that have low hexokinase II levels.
What is miR-126 and how does it fight cancer?
miR-126 is a tumor suppressor microRNA that is reduced in many cancers. Delivering it via a cancer-selective peptide restores its anti-cancer activity inside tumor cells.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05048APA
Palanikumar, L; Al-Hosani, Sumaya; Kalmouni, Mona; Saleh, Hadi Omar; Magzoub, Mazin. (2020). Hexokinase II-Derived Cell-Penetrating Peptide Mediates Delivery of MicroRNA Mimic for Cancer-Selective Cytotoxicity.. Biochemistry, 59(24), 2259-2273. https://doi.org/10.1021/acs.biochem.0c00141
MLA
Palanikumar, L, et al. "Hexokinase II-Derived Cell-Penetrating Peptide Mediates Delivery of MicroRNA Mimic for Cancer-Selective Cytotoxicity.." Biochemistry, 2020. https://doi.org/10.1021/acs.biochem.0c00141
RethinkPeptides
RethinkPeptides Research Database. "Hexokinase II-Derived Cell-Penetrating Peptide Mediates Deli..." RPEP-05048. Retrieved from https://rethinkpeptides.com/research/palanikumar-2020-hexokinase-iiderived-cellpenetrating-peptide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.